SAB Biotherapeutics, Inc.
SABSWNasdaq
$0.02
↑ +8.0%Jul 17 close · end-of-day
Price
1Y↓ -68.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$867,649.95
Enterprise Value
-$106.5M
P/E
—
P/S
—
P/B
0.0
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$398,429.00
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-0.2%
ROIC
-38.4%
Debt / Equity
—
Net Cash
$107.4M
Return 1Y
-68.7%
Company profile
SAB Biotherapeutics, Inc. engages in the development of immunotherapies based on human antibodies. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
- CEO
- Eddie J. Sullivan
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 140
- Headquarters
- Florida
- Website
- sabbiotherapeutics.com
Management & directors
- Kropotova AlexandraCHIEF MEDICAL OFFICER
Roles derived from SEC Form 4 filings.
Earnings
SABSW Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.35↓ -37.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $55.2M | $60.9M | $23.9M | $2.2M | $1.3M | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | $20.6M | -$13.4M | -$28.9M | -$38.1M | -$42.9M | -$49.0M |
| Net income | $20.1M | -$17.1M | -$18.7M | -$42.2M | -$34.1M | $13.3M |
| Diluted EPS | $0.74 | -$0.63 | -$4.31 | -$7.64 | -$3.68 | -$0.79 |
| Operating cash flow | $10.0M | $2.0M | -$23.5M | -$25.1M | -$34.3M | -$44.8M |
| Free cash flow | -$2.7M | -$9.0M | -$25.6M | -$25.3M | -$34.6M | -$45.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 37.2% | -22.0% | -121.0% | -1700.6% | -3244.9% | — |
| Net margin | 36.4% | -28.2% | -78.4% | -1884.5% | -2579.0% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $263,137.00 | $0.00 | $114,698.00 | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$10.2M | -$11.3M | -$10.0M | -$10.8M | -$9.7M | -$12.7M | -$15.8M | -$20.0M |
| Net income | -$7.3M | -$10.3M | -$11.4M | -$5.2M | -$10.1M | $45.4M | -$16.9M | -$18.9M |
| Diluted EPS | -$0.79 | -$1.12 | -$1.23 | -$0.56 | -$1.09 | -$0.21 | $1.07 | -$0.35 |
| Operating cash flow | -$7.7M | -$6.3M | -$9.5M | -$7.8M | -$7.2M | -$13.1M | -$16.8M | -$14.3M |
| Free cash flow | -$7.8M | -$6.4M | -$9.6M | — | — | — | — | -$15.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -3877.0% | — | -8726.3% | — | — | — | — | — |
| Net margin | -2787.7% | — | -9934.5% | — | — | — | — | — |
Company news
Jun 30, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-25 | Kropotova Alexandra· CHIEF MEDICAL OFFICER | Tax withholding | 988 | — | — | filing |
| 2026-03-24 | Kropotova Alexandra· CHIEF MEDICAL OFFICER | Tax withholding | 988 | — | — | filing |
| 2025-12-11 | Kropotova Alexandra· CHIEF MEDICAL OFFICER | Tax withholding | 988 | — | — | filing |
| 2025-09-29 | Moin Andrew | Option exercise | 1,740,000 | $1.75 | $3.0M | filing |
| 2025-09-29 | Sessa Capital (Master), L.P. | Option exercise | 1,740,000 | $1.75 | $3.0M | filing |
| 2025-09-19 | Kropotova Alexandra· CHIEF MEDICAL OFFICER | Tax withholding | 1,977 | — | — | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.